Related references
Note: Only part of the references are listed.Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
Lizza E. L. Hendriks et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Atezolizumab in patients with advanced non -small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study
Shirish M. Gadgeel et al.
LUNG CANCER (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017
Natsuki Takano et al.
LUNG CANCER (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies
Chiara D'Antonio et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases
A. Ali et al.
CURRENT ONCOLOGY (2013)
Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman et al.
CLINICAL CANCER RESEARCH (2010)
Trafficking of immune cells in the central nervous system
Emma H. Wilson et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Outcomes Associated with Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-small Cell Lung Cancer
Martin J. Edelman et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Immunohistochemical Markers Associated With Brain Metastases in Patients With Nonsmall Cell Lung Carcinoma
Ali G. Saad et al.
CANCER (2008)
Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors
Paulus Mrass et al.
IMMUNOLOGICAL REVIEWS (2006)
Current management of brain metastases, with a focus on systemic options
CJ Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
JS Barnholtz-Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Drug transport to the brain:: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier
M Demeule et al.
VASCULAR PHARMACOLOGY (2002)
Share Paper
